Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists

K Kintzoglanakis, C Diamantis… - … & Vascular Disease …, 2024 - journals.sagepub.com
The newfound knowledge in type 2 diabetes (T2D) during the past decade for the sodium-
glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists …

Tirzepatide for overweight and obesity management

M Hamza, D Papamargaritis… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction Tirzepatide is a once-weekly dual agonist, acting on glucagon-like peptide-1
(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is approved at …

Effects of semaglutide on muscle structure and function in the SLIM liver study

GL Ditzenberger, JE Lake, DW Kitch… - Clinical Infectious …, 2024 - academic.oup.com
Background Semaglutide is highly effective for decreasing weight. Concomitant loss of
muscle mass often accompanies weight loss and may have consequences on muscle …

Current Challenges, Solutions, and Novel Directions in Research and Clinical Care: Proceedings from the 14th Annual International Workshop on HIV and Aging

A Baim-Lance, S Cooley, M Yoo-Jeong… - The Journals of …, 2025 - academic.oup.com
Integrating antiretroviral therapy into HIV care dramatically extended the lifespan for people
living with HIV. Improving the health span requires understanding aging, HIV, associated …

Pharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease

RAR Abou Jaoudeh, P Hartmann… - Journal of pediatric …, 2024 - Wiley Online Library
Pediatric obesity, characterized by a body mass index (BMI) at or above the 95th percentile
for age, affects a substantial number of children and adolescents worldwide. Metabolic …

Impact of exercise training in combination with dapagliflozin on physical function in adults with type 2 diabetes mellitus: study protocol for the Dapagliflozin, Exercise …

JA Sargeant, E Ahmad, E James, L Baker, JM Bilak… - BMJ open, 2024 - bmjopen.bmj.com
Introduction Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are associated with weight
loss, diverse cardiorenal benefits and improved glycaemic control. However, the effects of …